 Corvus Pharmaceuticals shares jumped after the clinical-stage biopharm said it had initiated a Phase I study of a novel immunotherapy approach for coronavirus patients. At last check Corvus shares were up more than 90 at 5.25. Corvus said administration of an antibody designated as CPI-006, which has been used to treat cancer patients, led to increased levels of memory B cells, the cells responsible for long-term immunity. 